A multicenter, open label trial of azithromycin vs amoxicillin/clavulanate for the management of acute otitis media in children

被引:39
作者
Aronovitz, G
机构
[1] EMORY MED SCH,DEPT PEDIAT,ATLANTA,GA
[2] CHILDRENS HOSP MICHIGAN,DETROIT,MI 48201
[3] UNIV ALABAMA,BIRMINGHAM,AL
[4] MEM MILLER CHILDRENS HOSP,LONG BEACH,CA
关键词
pediatric; acute otitis media; azithromycin; amoxicillin/clavulanate;
D O I
10.1097/00006454-199609009-00003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective, This randomized, open label study compared the efficacy and safety of a Ei-day course of once daily azithromycin to those of a 10-day course of three times daily amoxicillin/clavulanate. Methods, One hundred sixty-nine children with confirmed acute bacterial otitis media were randomized to treatment with 10 mg/kg of azithromycin oral suspension on Day 1, followed by 5 mg/kg once daily for the next 4 days or 40 mg/kg/day of amoxicillin/clavulanate suspension in three divided doses for 10 days, Clinical efficacy and safety were evaluated on Days 11 and 30. Results. Analysis of evaluable patients 11 days after the start of treatment demonstrated that 87.8% of patients treated with azithromycin and 100.0% of the patients treated with amoxicillin/ clavulanate were cured or improved, Presumed bacteriologic eradication of the baseline pathogens Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes was comparable in the two groups: 87.8% in patients treated with azithromycin; and 100.0% in patients receiving amoxicillin/clavulanate, At Day 30, 82.2% of patients treated with azithromycin and 80.0% of patients treated with amoxicillin/clavulanate were cured or improved, Presumed bacteriologic eradication of the baseline pathogens was similar in the two groups: 82.2% in patients treated with azithromycin; and 81.1% in patients receiving amoxicillin/clavulanate, Relapses occurred in 5.1% of patients receiving azithromycin and 21.1% of patients taking amoxicillin/clavulanate (P = 0.047), Treatment-related side effects occurred in 3.5% of the azithromycin patients compared with 31.0% of amoxicillin/clavulanate patients (P < 0.001). Conclusions. Azithromycin was comparable to amoxicillin/clavulanate in achieving clinical cure or improvement and presumed eradication of baseline pathogens in pediatric patients with acute otitis media, Azithromycin was significantly better tolerated and was associated with fewer relapses than seen after amoxicillin/clavulanate therapy.
引用
收藏
页码:S15 / S19
页数:5
相关论文
共 19 条
[1]  
DANIEL RR, 1990, INT C INF DIS MONTR
[2]   THE INVITRO ACTIVITY OF CP-62,993 AGAINST HEMOPHILUS-INFLUENZAE, BRANHAMELLA-CATARRHALIS, STAPHYLOCOCCI AND STREPTOCOCCI [J].
DUNKIN, KT ;
JONES, S ;
HOWARD, AJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 21 (04) :405-411
[3]   INVITRO AND INVIVO UPTAKE OF AZITHROMYCIN (CP-62,993) BY PHAGOCYTIC-CELLS - POSSIBLE MECHANISM OF DELIVERY AND RELEASE AT SITES OF INFECTION [J].
GLADUE, RP ;
BRIGHT, GM ;
ISAACSON, RE ;
NEWBORG, MF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (03) :277-282
[4]   CLINICAL SAFETY AND TOLERANCE OF AZITHROMYCIN IN CHILDREN [J].
HOPKINS, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 :111-117
[5]   CLINICAL TOLERATION AND SAFETY OF AZITHROMYCIN [J].
HOPKINS, S .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 :S40-S45
[6]  
KHURANA C, 1994, 34 INT C ANT AG CHEM
[7]   DOUBLE-BLIND AND OPEN-LABEL STUDIES OF AZITHROMYCIN IN THE MANAGEMENT OF ACUTE OTITIS-MEDIA IN CHILDREN - A REVIEW [J].
MCLINN, S .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (04) :S62-S66
[8]   PHARMACOKINETICS OF AZITHROMYCIN IN PEDIATRIC-PATIENTS AFTER ORAL-ADMINISTRATION OF MULTIPLE DOSES OF SUSPENSION [J].
NAHATA, MC ;
KORANYI, KI ;
GADGIL, SD ;
HILLIGOSS, DM ;
FOUDA, HG ;
GARDNER, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :314-316
[9]   CLINICAL MICROBIOLOGY OF AZITHROMYCIN [J].
NEU, HC .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 :S12-S18
[10]   AZITHROMYCIN - A REVIEW OF ITS ANTIMICROBIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND CLINICAL EFFICACY [J].
PETERS, DH ;
FRIEDEL, HA ;
MCTAVISH, D .
DRUGS, 1992, 44 (05) :750-799